Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantern Pharma Inc. (NASDAQ: LTRN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as an AI-driven, clinical-stage oncology and pharmaceutical preparation manufacturing issuer. Through documents filed with the U.S. Securities and Exchange Commission, investors can review how Lantern reports its financial condition, governance decisions, and material events related to its RADR® AI platform and oncology drug pipeline.
Lantern files annual reports on Form 10-K and quarterly reports on Form 10-Q that describe its business model, risk factors, clinical programs such as LP-184, LP-284, and LP-300, and the role of its RADR® artificial intelligence and machine learning platform in oncology drug discovery and development. Current reports on Form 8-K disclose specific material events, including quarterly financial results, at-the-market equity offering agreements, changes to bylaws, board appointments, and outcomes of annual stockholder meetings, such as director elections and equity incentive plan matters.
Proxy materials, including definitive proxy statements on Schedule 14A, outline Lantern’s corporate governance structure, proposals submitted to stockholders, and details on topics like the repricing of stock options under its equity incentive plan or the ratification of independent auditors. These filings help investors understand how Lantern’s board and management approach capital structure, executive compensation, and shareholder rights as the company advances its AI-enabled oncology strategy.
On Stock Titan, Lantern’s SEC filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussion of the RADR® platform, clinical trial progress, regulatory designations, and financing arrangements. Users can monitor real-time updates from EDGAR, review historical filings for context on LTRN’s evolution, and examine governance and compensation disclosures alongside clinical and platform milestones. This page is a central reference for anyone analyzing Lantern Pharma’s regulatory record, from long-form 10-K narratives to focused 8-K announcements.
Panna Sharma, President & CEO and a director of Lantern Pharma Inc. (LTRN), amended an outstanding stock option originally granted on 06/15/2020. The amendment, recorded with a transaction date of 09/19/2025, canceled the prior option with a $15 exercise price covering 76,628 underlying shares and replaced it with a new option covering the same 76,628 shares at a reduced exercise price of $5.04. The option retains its original exercisability and expiration schedule (vested schedule described in the filing) and the replacement option shows 76,628 shares beneficially owned following the amendment. The form is signed by Ms. Sharma on 09/22/2025.
Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), filed a Form 4 reporting amendments to previously granted stock options. The filing shows two option amendments: a June 15, 2020 option was cancelled and replaced with a $5.04 exercise-price option covering 52,200 shares exercisable through 06/14/2030; a October 29, 2021 option was cancelled and replaced with a $5.04 exercise-price option covering 17,400 shares exercisable through 10/28/2031. After the replacements, Mr. Bhatia beneficially owns 52,200 and 17,400 underlying common shares for the respective options.
D. Jeffrey Keyser, a director of Lantern Pharma Inc. (LTRN), reported amendments to two outstanding stock options on a Form 4 covering transactions dated 09/19/2025. Each amendment cancelled an "old" option and granted a replacement option with a reduced exercise price while retaining the original grant dates and expiration dates. The June 15, 2020 option for 9,135 shares was changed from a $15.00 exercise price to $5.04 and remains exercisable through 06/14/2030. The November 4, 2021 option for 3,200 shares was changed from a $10.32 exercise price to $5.04 and remains exercisable through 11/03/2031. Both options vest on the original monthly 36-month schedules.
Lantern Pharma director and Chief Financial Officer David R. Margrave reported amendments to two previously granted stock options that reduced the exercise prices and replaced the canceled options with new options. One option originally granted June 15, 2020 for 78,300 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 06/14/2030, resulting in a held position of 78,300 underlying shares. A second option originally granted October 29, 2021 for 26,100 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 10/28/2031, resulting in a held position of 26,100 underlying shares. The filing is limited to these option amendments and the reporting person’s relationship as Director and Chief Financial Officer.
Lantern Pharma Inc. (LTRN): Director David S. Silberstein reported amendments to two outstanding stock options on 09/19/2025 that reduced the exercise prices and replaced the prior options. The first option originally granted 06/15/2020 (exercise price $15) for 9,135 shares was cancelled and replaced with a $5.04 option exercisable through 06/14/2030, leaving 9,135 underlying shares beneficially owned. The second option originally granted 11/04/2021 (exercise price $10.32) for 3,200 shares was cancelled and replaced with a $5.04 option exercisable through 11/03/2031, leaving 3,200 underlying shares beneficially owned. The filings note standard monthly vesting schedules for each original grant and the form is signed 09/22/2025.
Lantern Pharma (LTRN) director Lee T. Schalop was granted a stock option award for 5,000 shares under the companys Amended and Restated 2018 Equity Incentive Plan. The option has an exercise price of $4.46 and was granted with a transaction date of 08/19/2025. The award becomes exercisable in equal monthly increments over a 36-month vesting period commencing 09/19/2025 and expires 08/18/2035. The filing reports 5,000 underlying shares held directly following the grant. The Form 4 was submitted by the reporting person, who is identified as a director of the issuer.
Lantern Pharma Inc. reported in a Current Report on Form 8-K dated August 13, 2025 that it will issue a press release announcing its financial results for the second quarter ended June 30, 2025. The Company furnished the press release as Exhibit 99.1 and included a cover page interactive data file as Exhibit 104.
The filing notes the disclosure is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference into other filings. The document identifies Lantern Pharma as an emerging growth company, indicates it elected not to use the extended transition period for new accounting standards, lists its Nasdaq ticker LTRN, principal executive office in Dallas, Texas, and is signed by CFO David R. Margrave.
Lantern Pharma Inc. (LTRN) reported continuing operating losses as it advances three clinical-stage small-molecule candidates and an ADC program while relying on its RADR® A.I. platform. For the six months ended June 30, 2025, the company recorded a net loss of $8,867,798 versus $10,400,316 a year earlier, and net loss per share of $0.82 versus $0.97. Cash and cash equivalents were $6,061,408 and marketable securities were $9,840,366, giving approximately $15.9 million of combined liquidity and working capital of about $12.3 million.
The company noted a substantial doubt about its ability to continue as a going concern absent additional financing but expects existing resources to fund operations into June 2026. In July 2025 Lantern entered an ATM Sales Agreement to offer up to $15.53 million of common stock and sold 15,185 shares for approximately $80,000 through August 12, 2025. Research and development expense decreased to $6.33 million for the six months ended June 30, 2025 from $8.14 million a year earlier, while general and administrative expense was roughly stable at about $3.09 million. The company continues active clinical programs for LP-300 (Phase 2), LP-184 (Phase 1) and LP-284 (Phase 1) and operates the RADR platform and a Starlight subsidiary for CNS development.
Lantern Pharma Inc. will hold its 2025 virtual Annual Meeting on September 19, 2025 at 11:00 a.m. Eastern. Only holders of record as of July 28, 2025 may vote; 10,784,725 shares of common stock were outstanding on the record date. Stockholders will vote to elect six directors, approve a one-time repricing of certain stock options under the 2018 Equity Incentive Plan, ratify EisnerAmper LLP as auditor, and approve an adjournment if needed.
The Board approved the repricing on July 24, 2025: Eligible options have exercise prices > $10 and total 314,633 options (about 25% of 1,235,331 outstanding options) are eligible. Subject to stockholder approval, those options would be amended to an exercise price of $5.04 (125% of the 10-day VWAP ending July 24) and will only be exercisable at that price if the holder remains a service provider through a vesting satisfaction date 12 months after stockholder approval. The Company will recognize any incremental compensation cost under ASC Topic 718. The Board recommends a vote FOR all proposals.